ReviewFrontiers in immunology2023

Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review.

Shugui Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.